Six questions and answers by MetrioPharm CEO Dr. Wolfgang Brysch on the compound MP1032 in COVID-19
Is MetrioPharm developing a compound for the treatment of COVID-19?
Wolfgang Brysch: We are developing our lead compound MP1032 for the treatment of chronic inflammatory diseases, with the molecule targeting oxidative stress. Oxidative stress also plays a central role in COVID-19 disease...
2019 was the year of spectacular news, generated from the field of aging research. Supposedly, scientists had succeeded in slowing down the aging process, stopping it, even reversing it. As if life was an hourglass and we had learned how to stop time from running out by popping a pill, or even how to reverse the life flow.
The connection between chronic inflammation and diseases of aging
Is there a
problem with increasing life expectancy? If you look at the graph of average
life years alone, the development over the last fifty years looks very
positive. This graph shows a steady upward trend, especially in Western
countries. People are getting older continuously.
There is, however, a second graph that has risen much slower: that of healthy life expectancy...
A report on the current projects of the MetrioPharm team
Timetables on the office
walls, e-mails with long to-do lists and meetings of all project groups: The
new year has started off busy. In order to move the MetrioPharm pipeline ahead
as planned, the team is coordinating several major projects simultaneously.
One of the most important is the completion of the Phase II trial in the indication psoriasis...